还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  

0 P/ J* Y1 J% b& e, r
Sub-category:
  h1 v+ ]3 ~9 P& L/ [( @Molecular Targets


7 a; g: \# V4 t. jCategory:
Tumor Biology


" K* s8 m# H7 k5 Y4 h' d# V- mMeeting:
: Y, n! O4 T/ `4 q2011 ASCO Annual Meeting


- d( L4 a, `5 C1 w' d- `Session Type and Session Title:
Poster Discussion Session, Tumor Biology
$ v' P  M4 I; k0 B

2 H. i( I, {3 ]- M3 b, \. K& mAbstract No:
9 a% k4 p8 e8 j5 W* k: x6 }10517
! H' n5 n" u# Y3 H, x
9 w, f' N. Q1 M4 ?6 ]8 z# }
) @' j  C* j9 }# z) L+ z7 d4 VCitation:
  g4 h' y1 E  j* [) h+ o2 zJ Clin Oncol 29: 2011 (suppl; abstr 10517)


Author(s):
3 ~' ~& \+ ?3 F" z) xJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
, t; W: d) H$ Y% T0 i


6 C( v, ?$ j8 x' _Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

, h$ l2 d4 B$ B$ R8 yAbstract Disclosures

Abstract:
( i! E$ {5 X- G2 L! J& ?0 i

3 t( P! v6 z$ i; \+ Y" ^Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

, v( e1 D5 x! ~/ M8 d5 _5 U2 z

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

" a6 ]3 D% l7 d  e6 a没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

3 W1 ?- k0 \" g6 Z化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

1 d* L. C$ f1 P* M% ^" }4 t. r易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
/ Q6 E" A5 |  o# k  fALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊